Regulation of neutrophil function by adenosine

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 4, 2012, Pages 856-864

  Barletta, Kathryn E ^a   Ley, Klaus ^b   Mehrad, Borna ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

adhesion; blood cells; chemotaxis; cytokines; host defense

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N ( 3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 2 CHLOROADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5' (N CYCLOPROPYL)CARBOXAMIDO ADENOSINE; 6 N CYCLOPENTYLADENOSINE; 8 (4 SULFOPHENYL)THEOPHYLLINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; ADENOSINE TRIPHOSPHATE; APADENOSON; ATL 146 E; ATL 193; ATL 202; BAY 606583; BINODENOSON; CALCIUM IONOPHORE; CHEMOKINE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; CYTOKINE; DIPYRIDAMOLE; FIBRINOGEN; FORMYLMETHIONYLLEUCYLPHENYLALANINE; PHORBOL 13 ACETATE 12 MYRISTATE; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL DAMAGE; CELL FUNCTION; CELL MIGRATION; CELL STIMULATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENDOTHELIUM CELL; GROWTH INHIBITION; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE MIGRATION; MEDIATOR; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REGULATORY MECHANISM; RESPIRATORY BURST;

ADENOSINE; ANIMALS; CELL ADHESION; CELL DEGRANULATION; CHEMOTAXIS, LEUKOCYTE; HUMANS; INFLAMMATION; NEUTROPHIL ACTIVATION; NEUTROPHILS; PHAGOCYTOSIS; RECEPTORS, PURINERGIC P1; RESPIRATORY BURST; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 84858661677     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.226845     Document Type: Article

References (93)

1. Harkness RA, Simmonds RJ, Coade SB. Purine transport and metabolism in man: the effect of exercise on concentrations of purine bases, nucleosides and nucleotides in plasma, urine, leucocytes and erythrocytes. Clin Sci. 1983;64:333-340. (Pubitemid 13173023)
2. Bours MJL, Swennen ELR, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5=-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006;112: 358-404. (Pubitemid 44486409)
3. Ontyd J, Schrader J. Measurement of adenosine, inosine, and hypoxanthine in human plasma. J Chromatogr. 1984;307:404-409. (Pubitemid 14102635)
4. Yoneyama Y, Suzuki S, Sawa R, Araki T. Plasma adenosine concentrations increase in women with hyperemesis gravidarum. Clin Chim Acta. 2004;342:99-103. (Pubitemid 38352918)
5. Fredholm BB. Purines and neutrophil leukocytes. Gen Pharmacol. 1997; 28:345-350. (Pubitemid 27116194)
6. Möser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989;256:C799-C806.
7. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201-212.
8. Fredholm BB, Zhang Y, van der Ploeg I. Adenosine A2A receptors mediate the inhibitory effect of adenosine on formyl-Met-Leu-Phestimulated respiratory burst in neutrophil leucocytes. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:262-267. (Pubitemid 26284490)
9. Cronstein BN, Daguma L, Nichols D, Hutchison AJ, Williams M. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively. J Clin Invest. 1990;85:1150-1157. (Pubitemid 20123757)
10. Gessi S, Varani K, Merighi S, Cattabriga E, Iannotta V, Leung E, Baraldi PG, Borea PA. A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. Mol Pharmacol. 2002;61:415-424. (Pubitemid 34112817)
11. Bouma MG, Jeunhomme TM, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FA, Buurman WA. Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. J Immunol. 1997;158:5400-5408. (Pubitemid 127681247)
12. Thiel M, Chambers JD, Chouker A, Fischer S, Zourelidis C, Bardenheuer HJ, Arfors KE, Peter K. Effect of adenosine on the expression of beta(2) integrins and L-selectin of human polymorphonuclear leukocytes in vitro. J Leukoc Biol. 1996;59:671-682. (Pubitemid 26198079)
13. Newby AC, Holmquist CA. Adenosine production inside rat polymorphonuclear leucocytes. Biochem J. 1981;200:399-403. (Pubitemid 12218262)
14. Worku Y, Newby AC. The mechanism of adenosine production in rat polymorphonuclear leucocytes. Biochem J. 1983;214:325-330. (Pubitemid 13035513)
15. Bengtsson T, Zalavary S, Stendahl O, Grenegård M. Release of oxygen metabolites from chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular adenosine and actin polymerization. Blood. 1996;87:4411-4423. (Pubitemid 26152283)
16. Mann JS, Renwick AG, Holgate ST. Release of adenosine and its metabolites from activated human leucocytes. Clin Sci. 1986;70:461-468. (Pubitemid 16142996)
17. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. A new physiological function for adenosine: regulation of superoxide anion production. Trans Assoc Am Physicians. 1983;96:384-391.
18. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med. 1983;158:1160-1177.
19. Kitakaze M, Hori M, Morioka T, Takashima S, Minamino T, Sato H, Inoue M, Kamada T. Attenuation of ecto-5=-nucleotidase activity and adenosine release in activated human polymorphonuclear leukocytes. Circ Res. 1993;73:524-533. (Pubitemid 23238738)
20. van Waeg G, Van den Berghe G. Purine catabolism in polymorphonuclear neutrophils. Phorbol myristate acetate-induced accumulation of adenosine owing to inactivation of extracellularly released adenosine deaminase. J Clin Invest. 1991;87:305-312.
21. Eltzschig HK, Eckle T, Mager A, Küper N, Karcher C, Weissmüller T, Boengler K, Schulz R, Robson SC, Colgan SP. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosinedependent endothelial cell function. Circ Res. 2006;99:1100-1108. (Pubitemid 44729934)
22. Eltzschig HK, Macmanus CF, Colgan SP. Neutrophils as sources of extracellular nucleotides: functional consequences at the vascular interface. Trends Cardiovasc Med. 2008;18:103-107. (Pubitemid 351626607)
23. Grassi F. Purinergic control of neutrophil activation. J Mol Cell Biol. 2010;2:176-177.
24. Madara JL, Parkos C, Colgan S, MacLeod RJ, Nash S, Matthews J, Delp C, Lencer W. Cl-secretion in a model intestinal epithelium induced by a neutrophil-derived secretagogue. J Clin Invest. 1992;89:1938-1944.
25. Madara JL, Patapoff TW, Gillece-Castro B, Colgan SP, Parkos CA, Delp C, Mrsny RJ. 5=-adenosine monophosphate is the neutrophil-derived paracrine factor that elicits chloride secretion from T84 intestinal epithelial cell monolayers. J Clin Invest. 1993;91:2320-2325. (Pubitemid 23141512)
26. Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5=-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J Exp Med. 1998;188:1433-1443. (Pubitemid 28489580)
27. Baldwin SA, Beal PR, Yao SYM, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004; 447:735-743. (Pubitemid 38241459)
28. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schönfeld C, Löffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med. 2005; 202:1493-1505. (Pubitemid 41746596)
29. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986;78:760-770. (Pubitemid 16024813)
30. Cronstein BN, Kubersky SM, Weissmann G, Hirschhorn R. Engagement of adenosine receptors inhibits hydrogen peroxide (H2O2) release by activated human neutrophils. Clin Immunol Immunopathol. 1987;42: 76-85. (Pubitemid 17231585)
31. Schrier DJ, Imre KM. The effects of adenosine agonists on human neutrophil function. J Immunol. 1986;137:3284-3289. (Pubitemid 17210024)
32. Rose FR, Hirschhorn R, Weissmann G, Cronstein BN. Adenosine promotes neutrophil chemotaxis. J Exp Med. 1988;167:1186-1194.
33. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314:1792-1795. (Pubitemid 44969094)
34. Inoue Y, Chen Y, Hirsh MI, Yip L, Junger WG. A3 and P2Y2 receptors control the recruitment of neutrophils to the lungs in a mouse model of sepsis. Shock. 2008;30:173-177.
35. Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, Junger WG. Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem. 2008;283:28480-28486.
36. Junger WG. Purinergic regulation of neutrophil chemotaxis. Cell Mol Life Sci. 2008;65:2528-2540.
37. Linden J. Cell biology. Purinergic chemotaxis. Science. 2006;314: 1689-1690.
38. Bouma MG, van den Wildenberg FA, Buurman WA. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am J Physiol. 1996;270:C522-C529.
39. Mirakaj V, Thix CA, Laucher S, Mielke C, Morote-Garcia JC, Schmit MA, Henes J, Unertl KE, Köhler D, Rosenberger P. Netrin-1 dampens pulmonary inflammation during acute lung injury. Am J Respir Crit Care Med. 2010;181:815-824.
40. Aherne CM, Collins CB, Masterson JC, Tizzano M, Boyle TA, Westrich JA, Parnes JA, Furuta GT, Rivera-Nieves J, Eltzschig HK. Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis [epub ahead of print August 3]. Gut. 2011.
41. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK. Hypoxia-inducible factordependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol. 2009;10:195-202.
42. Linden J. Regulation of leukocyte function by adenosine receptors. Adv Pharmacol. 2011;61:95-114.
43. Säve S, Mohlin C, Vumma R, Persson K. Activation of adenosine A2A receptors inhibits neutrophil transuroepithelial migration. Infect Immun. 2011;79:3431-3437.
44. Gunther GR, Herring MB. Inhibition of neutrophil superoxide production by adenosine released from vascular endothelial cells. Ann Vasc Surg. 1991;5:325-330.
45. Felsch A, Stöcker K, Borchard U. Phorbol ester-stimulated adherence of neutrophils to endothelial cells is reduced by adenosine A2 receptor agonists. J Immunol. 1995;155:333-338.
46. Zhao ZQ, Sato H, Williams MW, Fernandez AZ, Vinten-Johansen J. Adenosine A2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol. 1996;271:H1456-H1464.
47. Firestein GS, Bullough DA, Erion MD, Jimenez R, Ramirez-Weinhouse M, Barankiewicz J, Smith CW, Gruber HE, Mullane KM. Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor. The role of selectins. J Immunol. 1995;154:326-334.
48. Cronstein BN, Levin RI, Philips M, Hirschhorn R, Abramson SB, Weissmann G. Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol. 1992;148:2201-2206.
49. Wollner A, Wollner S, Smith JB. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cd11b/CD18) expression on FMLPstimulated neutrophils. Am J Respir Cell Mol Biol. 1993;9:179-185.
50. Sullivan GW, Lee DD, Ross WG, DiVietro JA, Lappas CM, Lawrence MB, Linden J. Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol. 2004;75:127-134. (Pubitemid 38166787)
51. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, Buckley MT, Carlin G, Cronstein BN. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol. 1996;156:1937-1941. (Pubitemid 26069328)
52. Glover DK, Riou LM, Ruiz M, Sullivan GW, Linden J, Rieger JM, Macdonald TL, Watson DD, Beller GA. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol. 2005;288:H1851-H1858. (Pubitemid 40418013)
53. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE, Gimple LW, Powers ER, Macdonald T, Sullivan G, Linden J, Sarembock IJ. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol. 2001;21:791-796. (Pubitemid 32448770)
54. Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, Vinten-Johansen J. A(3) adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol. 1999;277:H1895-H1905.
55. Narravula S, Lennon PF, Mueller BU, Colgan SP. Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J Immunol. 2000;165:5262-5268.
56. Eltzschig HK, Ibla JC, Furuta GT, Leonard MO, Jacobson KA, Enjyoji K, Robson SC, Colgan SP. Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors. J Exp Med. 2003;198: 783-796. (Pubitemid 37087777)
57. Thiel M, Chouker A. Acting via A2 receptors, adenosine inhibits the production of tumor necrosis factor-alpha of endotoxin-stimulated human polymorphonuclear leukocytes. J Lab Clin Med. 1995;126:275-282.
58. McColl SR, St-Onge M, Dussault A-A, Laflamme C, Bouchard L, Boulanger J, Pouliot M. Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J. 2006;20:187-189. (Pubitemid 43100509)
59. Cadieux J-S, Leclerc P, St-Onge M, Dussault A-A, Laflamme C, Picard S, Ledent C, Borgeat P, Pouliot M. Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci. 2005;118:1437-1447. (Pubitemid 40585124)
60. Pouliot M, Fiset M-E, Massé M, Naccache PH, Borgeat P. Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J Immunol. 2002;169:5279-5286. (Pubitemid 35217200)
61. Krump E, Lemay G, Borgeat P. Adenosine A2 receptor-induced inhibition of leukotriene B4 synthesis in whole blood ex vivo. Br J Pharmacol. 1996;117:1639-1644. (Pubitemid 26121607)
62. Krump E, Picard S, Mancini J, Borgeat P. Suppression of leukotriene B4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils. J Exp Med. 1997;186:1401-1406. (Pubitemid 27469037)
63. Surette ME, Krump E, Picard S, Borgeat P. Activation of leukotriene synthesis in human neutrophils by exogenous arachidonic acid: inhibition by adenosine A(2a) receptor agonists and crucial role of autocrine activation by leukotriene B(4). Mol Pharmacol. 1999;56:1055-1062.
64. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P. Cyclic AMPmediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol. 2002;62:250-256. (Pubitemid 34804103)
65. Flamand N, Boudreault S, Picard S, Austin M, Surette ME, Plante H, Krump E, Vallée MJ, Gilbert C, Naccache P, Laviolette M, Borgeat P. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am J Respir Crit Care Med. 2000;161:S88-S94. (Pubitemid 30129423)
66. Salmon JE, Cronstein BN. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol. 1990;145: 2235-2240. (Pubitemid 20343390)
67. Zalavary S, Stendahl O, Bengtsson T. The role of cyclic AMP, calcium and filamentous actin in adenosine modulation of Fc receptor-mediated phagocytosis in human neutrophils. Biochim Biophys Acta. 1994;1222: 249-256. (Pubitemid 24213657)
68. Richter J. Effect of adenosine analogues and cAMP-raising agents on TNF-, GM-CSF-, and chemotactic peptide-induced degranulation in single adherent neutrophils. J Leukoc Biol. 1992;51:270-275.
69. Visser SS, Theron AJ, Ramafi G, Ker JA, Anderson R. Apparent involvement of the A(2A) subtype adenosine receptor in the antiinflammatory interactions of CGS 21680, cyclopentyladenosine, and IB-MECA with human neutrophils. Biochem Pharmacol. 2000;60: 993-999.
70. Anderson R, Visser SS, Ramafi G, Theron AJ. Accelerated resequestration of cytosolic calcium and suppression of the pro-inflammatory activities of human neutrophils by CGS 21680 in vitro. Br J Pharmacol. 2000;130:717-724. (Pubitemid 30389049)
71. Sullivan GW, Linden J, Buster BL, Scheld WM. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: synergy with the type IV phosphodiesterase inhibitor, rolipram. J Infect Dis. 1999;180:1550-1560. (Pubitemid 29506457)
72. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6:173-182. (Pubitemid 43290987)
73. Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R. Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol. 1985;135:1366-1371. (Pubitemid 16237462)
74. Thiel M, Holzer K, Kreimeier U, Moritz S, Peter K, Messmer K. Effects of adenosine on the functions of circulating polymorphonuclear leukocytes during hyperdynamic endotoxemia. Infect Immun. 1997;65: 2136-2144. (Pubitemid 27237289)
75. Sullivan GW, Rieger JM, Scheld WM, Macdonald TL, Linden J. Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists. Br J Pharmacol. 2001;132:1017-1026. (Pubitemid 32238907)
76. Stewart AG, Harris T. Adenosine inhibits platelet-activating factor, but not tumour necrosis factor-alpha-induced priming of human neutrophils. Immunology. 1993;78:152-158. (Pubitemid 23035863)
77. Zalavary S, Bengtsson T. Adenosine inhibits actin dynamics in human neutrophils: evidence for the involvement of cAMP. Eur J Cell Biol. 1998;75:128-139. (Pubitemid 28138177)
78. Sullivan GW, Carper HT, Mandell GL. The specific type IV phosphodiesterase inhibitor rolipram combined with adenosine reduces tumor necrosis factor-alpha-primed neutrophil oxidative activity. Int J Immunopharmacol. 1995;17:793-803.
79. Kubersky SM, Hirschhorn R, Broekman MJ, Cronstein BN. Occupancy of adenosine receptors on human neutrophils inhibits respiratory burst stimulated by ingestion of complement-coated particles and occupancy of chemoattractant but not Fc receptors. Inflammation. 1989;13:591-599. (Pubitemid 19260776)
80. Swain SD, Siemsen DW, Nelson LK, Sipes KM, Hanson AJ, Quinn MT. Inhibition of the neutrophil NADPH oxidase by adenosine is associated with increased movement of flavocytochrome b between subcellular fractions. Inflammation. 2003;27:45-58. (Pubitemid 36359895)
81. Cronstein BN, Haines KA, Kolasinski S, Reibman J. Occupancy of G alpha s-linked receptors uncouples chemoattractant receptors from their stimulus-transduction mechanisms in the neutrophil. Blood. 1992;80: 1052-1057.
82. Thibault N, Harbour D, Borgeat P, Naccache PH, Bourgoin SG. Adenosine receptor occupancy suppresses chemoattractant-induced phospholipase D activity by diminishing membrane recruitment of small GTPases. Blood. 2000;95:519-527. (Pubitemid 30041664)
83. van der Hoeven D, Wan TC, Gizewski ET, Kreckler LM, Maas JE, Van Orman J, Ravid K, Auchampach JA. A role for the low-affinity A2B adenosine receptor in regulating superoxide generation by murine neutrophils. J Pharmacol Exp Ther. 2011;338:1004-1012.
84. Walker BA, Rocchini C, Boone RH, Ip S, Jacobson MA. Adenosine A2a receptor activation delays apoptosis in human neutrophils. J Immunol. 1997;158:2926-2931. (Pubitemid 127470555)
85. Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Nakazawa T, Komiyama A. Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol. 2000;67:529-535.
86. Thiagarajan RR, Winn RK, Harlan JM. The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost. 1997;78:310-314. (Pubitemid 27289260)
87. Polanowska-Grabowska R, Wallace K, Field JJ, Chen L, Marshall MA, Figler R, Gear ARL, Linden J. P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease. Arterioscler Thromb Vasc Biol. 2010;30:2392-2399.
88. Jordan JE, Zhao ZQ, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther. 1997;280:301-309. (Pubitemid 27171416)
89. Wallace KL, Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood. 2010;116:5010-5020.
90. Reutershan J, Cagnina RE, Chang D, Linden J, Ley K. Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol. 2007;179: 1254-1263.
91. Sullivan GW, Fang G, Linden J, Scheld WM. A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis. 2004;189:1897-1904. (Pubitemid 38657226)
92. Lappas CM, Day Y-J, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med. 2006;203: 2639-2648. (Pubitemid 44833340)
93. Németh ZH, Csóka B, Wilmanski J, Xu D, Lu Q, Ledent C, Deitch EA, Pacher P, Spolarics Z, Haskó G. Adenosine A2A receptor inactivation increases survival in polymicrobial sepsis. J Immunol. 2006;176: 5616-5626.